Last reviewed · How we verify
NCT03872882
Accuscreen Equipment Evaluation For Newborn Hearing Screening
trial in Hearing Loss in 100 participants. Completed in 13 December 2017.
13 December 2017
Quick facts
| Lead sponsor | Julie Dawson |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 22 March 2017 |
| Primary completion | 13 December 2017 |
| Estimated completion | 13 December 2017 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Hearing Loss — all drugs for Hearing Loss →
Sponsor
Julie Dawson — full company profile →
Who can join
Adults 1 Day to 4 Days, any sex, with Hearing Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An evaluation and comparison of results between the 'Accuscreen New' currently in use and an 'Accuscreen New' with different settings to see if the new settings reduce unnecessary referrals for babies from newborn hearing screening. Babies will be tested with the standard and modified equipment. Referrals for diagnostic testing will be based on the standard equipment. A comparison in referrals between the standard and modified equipment will be made.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03872882
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hearing Loss
Currently open trials in the same condition.
- NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
- NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
- NCT07218913 — Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III · Phase 1 · recruiting
- NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Julie Dawson trials
Trials by the same sponsor.
- NCT04142905 — Is Asthma in Subjects With Obstructive Sleep Apnoea (OSA) Due to Dysanapsis · unknown
- NCT04156763 — Virtual Reality Test of Strabismus · terminated
- NCT04031131 — The Use of Topical Anaesthetic in the Banding of Internal Haemorrhoids · Phase 2 · completed
- NCT04014647 — Measurement Of NT-proBNP to Predict Outcomes in Surgery · suspended
- NCT04026516 — CAVA: Dizziness Trial · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03872882 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Julie Dawson
- Last refreshed: 8 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03872882.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing